Measles

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine

18100%

+ 56 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

BiocorpFrance - Issoire

3 programs

MMR VaccinePhase 4Vaccine1 trial

MMR Bio-ManguinhosPhase 3

Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases ConfirmedN/AVaccine1 trial

Active Trials

NCT05592756Completed2,964Est. Mar 2022

NCT01777529Completed240Est. Dec 2013

MSDIreland - Ballydine

17 programs

Comparator: M-M-RPhase 3

Comparator: ProQuad™Phase 3

M-M-R™II manufactured with recombinant Human AlbuminPhase 3

MMRVPhase 3

Measles, Mumps, Rubella and VaricellaPhase 3

+12 more programs

Sharp TherapeuticsPA - Pittsburgh

17 programs

Comparator: M-M-RPhase 3

Comparator: ProQuad™Phase 3

M-M-R™II manufactured with recombinant Human AlbuminPhase 3

MMRVPhase 3

Measles, Mumps, Rubella and VaricellaPhase 3

+12 more programs

ViiV HealthcareNC - Durham

8 programs

MMR Bio-ManguinhosPhase 31 trial

MMRVNSPhase 31 trial

MeMuRu-OKAPhase 31 trial

Measles, Mumps, Rubella and ChickenpoxPhase 31 trial

PriorixPhase 31 trial

+3 more programs

Active Trials

NCT02712203Unknown5,808Est. Dec 2016

NCT00892775Completed501Est. Dec 2010

NCT01991899Completed1,560Est. Jul 2016

+5 more trials

Nordic PharmaFrance - Paris

1 program

MVA-mBN85BPhase 21 trial

Active Trials

NCT00891007Completed90Est. Aug 2010

Allergy TherapeuticsUK - West Sussex

3 programs

MMR-IIPhase 1/21 trial

Measles vaccineN/AVaccine1 trial

Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella VaccinesN/A1 trial

Active Trials

NCT02058927Completed203Est. Feb 2012

NCT00138255Terminated32Est. Jun 2005

NCT00258726Terminated105Est. Jul 2007

Merck & Co.RAHWAY, NJ

12 programs

MMR vaccineN/AVaccine1 trial

Measles, Mumps, Rubella and VaricellaPHASE_22 trials

V205C, measles, mumps, and rubella virus vaccine livePHASE_2Vaccine1 trial

measles, mumps, and rubella virus vaccine livePHASE_2Vaccine1 trial

M-M-R™II manufactured with recombinant Human AlbuminPHASE_31 trial

+7 more programs

Active Trials

NCT00962819Completed74Est. Dec 2012

NCT00839917Terminated30Est. May 2008

NCT00986232Completed1,551Est. Sep 2000

+10 more trials

GSKLONDON, United Kingdom

8 programs

MMR vaccine / MMRV vaccineN/AVaccine

Priorix-TetraPHASE_2

MMR Bio-ManguinhosPHASE_3

MMRVNSPHASE_3

MeMuRu-OKAPHASE_3

+3 more programs

Novo NordiskBAGSVAERD DENMARK, Denmark

3 programs

Measles vaccinePHASE_4Vaccine1 trial

Active Trials

NCT00168545Completed400Est. Jan 2007

NCT00168558Completed5,879Est. Mar 2008

NCT00168571Completed1,960Est. Jan 2007

Bavarian NordicDenmark - Kvistgard

1 program

MVA-mBN85BPHASE_2

SanofiPARIS, France

1 program

Inactivated Hep A vaccine; Attenuated Measles Mumps RubellaPHASE_4Vaccine1 trial

Active Trials

NCT00313950Completed470Est. Apr 2010

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

BiocorpMMR Vaccine

SanofiInactivated Hep A vaccine; Attenuated Measles Mumps Rubella

Novo NordiskMeasles vaccine

ViiV HealthcareMMRVNS

ViiV HealthcareMMR Bio-Manguinhos

ViiV HealthcarePriorix

Merck & Co.MMRV

ViiV HealthcarePriorixTM

Merck & Co.Measles, Mumps, Rubella and Varicella

Merck & Co.ProQuad® manufactured with recombinant Human Albumin

Merck & Co.ProQuad®

ViiV HealthcareMeMuRu-OKA

Showing 15 of 31 trials with date data

Clinical Trials (31)

Total enrollment: 45,346 patients across 31 trials

NCT01777529 BiocorpMMR Vaccine

Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations

Start: Oct 2012Est. completion: Dec 2013240 patients

Phase 4Completed

NCT00313950 SanofiInactivated Hep A vaccine; Attenuated Measles Mumps Rubella

Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine

Start: Sep 2006Est. completion: Apr 2010470 patients

Phase 4Completed

NCT00168545 Novo NordiskMeasles vaccine

Immunology of Non-specific Effects of Vaccine

Start: Jan 2006Est. completion: Jan 2007400 patients

Phase 4Completed

NCT00168558 Novo NordiskMeasles vaccine

Early Two-dose Measles Vaccination Trial

Start: Jul 2003Est. completion: Mar 20085,879 patients

Phase 4Completed

NCT00168571 Novo NordiskMeasles vaccine

Long-term Follow-up of Measles Antibodies

Start: Mar 2002Est. completion: Jan 20071,960 patients

Phase 4Completed

NCT07406360 ViiV HealthcareMMRVNS

A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age

Start: Apr 2026Est. completion: Jun 20281,209 patients

Phase 3Not Yet Recruiting

NCT01991899 ViiV HealthcareMMR Bio-Manguinhos

Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.

Start: Feb 2015Est. completion: Jul 20161,560 patients

Phase 3Completed

NCT01681992 ViiV HealthcarePriorix

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Start: Oct 2012Est. completion: Aug 20154,538 patients

Phase 3Completed

NCT01536405 Merck & Co.MMRV

Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)

Start: Jun 2012Est. completion: Jan 20141,412 patients

Phase 3Completed

NCT00751348 ViiV HealthcarePriorixTM

Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136

Start: Oct 2008Est. completion: May 2010475 patients

Phase 3Completed

NCT00839917 Merck & Co.Measles, Mumps, Rubella and Varicella

A Study of ProQuad™ in Healthy Children in Korea (V221-023)

Start: Feb 2008Est. completion: May 200830 patients

Phase 3Terminated

NCT00566527 Merck & Co.ProQuad® manufactured with recombinant Human Albumin

Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)

Start: Nov 2007Est. completion: Dec 20081,620 patients

Phase 3Completed

NCT00560755 Merck & Co.ProQuad®

Safety Study of ProQuad® rHA in Infants (V221-037)

Start: Oct 2007Est. completion: Nov 20083,388 patients

Phase 3Completed

NCT00402831 Merck & Co.ProQuad®

ProQuad® Intramuscular vs Subcutaneous

Start: Oct 2006Est. completion: May 2007405 patients

Phase 3Completed

NCT00351923 ViiV HealthcareMeMuRu-OKA

Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes

Start: Mar 2006Est. completion: Dec 2006330 patients

Phase 3Completed

NCT00127010 ViiV HealthcareMeasles, Mumps, Rubella and Chickenpox

Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Start: Nov 2005Est. completion: Jun 2006

Phase 3Completed

NCT00432523 Merck & Co.M-M-R™II manufactured with recombinant Human Albumin

Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

Start: Jan 2005Est. completion: Sep 2005752 patients

Phase 3Completed

NCT00092430 Merck & Co.V221, measles, mumps, rubella and varicella

Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)

Start: Sep 2002Est. completion: Jun 20031,200 patients

Phase 3Completed

NCT00984295 Merck & Co.Measles, Mumps, Rubella and Varicella

Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines

Start: Jun 2000Est. completion: Dec 20011,913 patients

Phase 3Completed

NCT00985153 Merck & Co.Measles, Mumps, Rubella and Varicella

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

Start: Mar 2000Est. completion: May 20013,927 patients

Phase 3Completed

NCT00892775 ViiV HealthcarePriorix-Tetra

Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds

Start: Jun 2009Est. completion: Dec 2010501 patients

Phase 2Completed

NCT00891007 Nordic PharmaMVA-mBN85B

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

Start: Jun 2009Est. completion: Aug 201090 patients

Phase 2Completed

NCT00109278 Merck & Co.V205C, measles, mumps, and rubella virus vaccine live

A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)

Start: Oct 2004Est. completion: May 20051,100 patients

Phase 2Completed

NCT00092404 Merck & Co.measles, mumps, and rubella virus vaccine live

Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)

Start: Dec 2001Est. completion: Jun 20051,210 patients

Phase 2Completed

NCT00986232 Merck & Co.Measles, Mumps, Rubella and Varicella

ProQuad Dose Selection Study (V221-011)(COMPLETED)

Start: Apr 1999Est. completion: Sep 20001,551 patients

Phase 2Completed

NCT00258726 Allergy TherapeuticsMMR-II

Immune Responses to Two Dose Varivax +/- MMR-II

Start: Oct 2005Est. completion: Jul 2007105 patients

Phase 1/2Terminated

NCT05592756 BiocorpSecondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed

Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed

Start: Apr 2020Est. completion: Mar 20222,964 patients

N/ACompleted

NCT02058927 Allergy TherapeuticsMeasles vaccine

Immune Reconstitution to Measles Virus of HIV Infected Children in Zambia

Start: May 2011Est. completion: Feb 2012203 patients

N/ACompleted

NCT00962819 Merck & Co.MMR vaccine

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Start: Mar 2010Est. completion: Dec 201274 patients

N/ACompleted

NCT02712203 ViiV HealthcareMMR vaccine / MMRV vaccine

MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.

Start: Jul 2004Est. completion: Dec 20165,808 patients

N/AUnknown

NCT00138255 Allergy TherapeuticsResponses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines

Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines

Start: Jun 2004Est. completion: Jun 200532 patients

N/ATerminated

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

33 late-stage (Phase 3) programs, potential near-term approvals

11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.